HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. - Wikidata - wikimedia - TriplyDB

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.

http://www.wikidata.org/entity/Q34527469

about

Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies Patterns of HIV/SIV Prevention and Control by Passive Antibody Immunization Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection Advancements in Developing Strategies for Sterilizing and Functional HIV Cures.Early antibody therapy can induce long-lasting immunity to SHIV Antibody 10-1074 suppresses viremia in HIV-1-infected individuals Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller Antiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design.HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success.NK Cells Expressing the Inhibitory Killer Immunoglobulin-Like Receptors (iKIR) KIR2DL1, KIR2DL3 and KIR3DL1 Are Less Likely to Be CD16+ than Their iKIR Negative Counterparts Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.Role of Natural Killer Cells in HIV-Associated Malignancies.Of Mice, Macaques, and Men: Broadly Neutralizing Antibody Immunotherapy for HIV-1.Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults.Use of broadly neutralizing antibodies for HIV-1 prevention.Approaches to the induction of HIV broadly neutralizing antibodies.Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza.B-cell responses to HIV infection.Anti-retroviral antibody FcγR-mediated effector functions.Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies.From dendritic cells to B cells dysfunctions during HIV-1 infection: T follicular helper cells at the crossroads.Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection.Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field.Universal antiretroviral regimens: thinking beyond one-pill-once-a-day.Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.How germinal centers evolve broadly neutralizing antibodies: the breadth of the follicular helper T cell response.Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers.Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys.Peptide Paratope Mimics of the Broadly Neutralizing HIV-1 Antibody b12.Env-Specific Antibodies in Chronic Infection versus in Vaccination.A potent human neutralizing antibody Fc-dependently reduces established HBV infections Time-course, negative-stain electron microscopy-based analysis for investigating protein-protein interactions at the single-molecule level.

P2860

Q27468870-6F28E2AF-AAB5-4A4B-B9D9-889061073549 Q28066335-723724F5-4227-4B94-97DB-9EDF2EB94371 Q28068018-AF4E2071-434D-4F2E-BA69-BFBE48A55028 Q28079455-FABA1915-7213-4340-B0EC-1D85A3C7F89D Q33592852-D1213B7A-B2DB-443C-A039-50C8550869C2 Q33620546-83E9081B-37DE-452C-8109-E9B7D9CEA017 Q33654409-D59C8600-C544-41AE-9CAB-D1B818FCE0AC Q33762877-5106C4EF-CDA8-4B1A-A254-4DB5572A9AF4 Q33786443-5FE8D1D4-C5FD-4DF7-BF09-51F2F0CD7F2C Q33786447-8B035B1A-0103-4873-990A-28ADA3FE4E52 Q33867299-75AC2C91-1654-47E9-B861-4F610B8A8C84 Q34531858-69C73665-352B-4453-B259-C49195C86E81 Q34550046-5DAFA7F8-F7E6-4AC8-A3EC-AFD34BC86754 Q36161508-99830EA2-9FBF-435A-95EA-12BDA27771B9 Q37593177-E39AE8D3-6A27-431A-8670-C6F909B2CBB6 Q37621530-A1F40B22-0DFA-48B8-8C03-B7D29BA843BE Q37624842-809E743A-1C22-455D-A3AA-2B3B19DD91E9 Q37712593-77503C60-92DA-47D6-B346-4881E9CC213F Q38643834-08B4D623-9CC4-4B45-BF13-466B2D354CBC Q38673539-C5408806-AA91-4337-A740-6C3905B94962 Q38736222-E37C3CF1-1250-4755-BAB8-912B9856D4C4 Q38764543-322D66DA-558D-4CE5-87D3-13950ACA8800 Q38936867-115EC634-C3E7-4BB1-8445-F6B41C347469 Q38977425-97377188-81D0-4148-A41A-BBDEE29B5034 Q38983251-B7FA4AF0-8A86-47E0-82FA-79D444F5F326 Q39108710-2A12F59C-A0A2-42DE-BE1C-DE593203F41D Q39108744-47723537-5E54-40DE-9D38-8456145DA23A Q39108760-A92D8F2D-E0A9-4892-92B0-43336F3F8296 Q39148138-98FFB72D-7C41-411A-BF86-DC9986F99CC6 Q39170404-4C674921-DF25-4A05-91B8-0EFCBBA60A05 Q39189458-5BF85EEB-A815-4705-8541-374B7F9BC6D3 Q39215169-D5613A0E-4D7E-4060-8B03-7D24A9764467 Q39407795-E26C07AA-69D5-45CB-A09A-C14F57715502 Q40054979-4E689886-178C-4094-A603-06BCDB96B61E Q40076041-F1EF1836-90B7-41D0-B582-4D433F4EABEE Q40187584-3A2BEC50-0A01-4005-8FE4-47AAB334A697 Q40357100-4E3251AD-C463-4683-9693-BB9F029CC060 Q41475637-5743D825-5D78-4213-AA8E-49D38A0AA47F Q41671765-0B4669ED-9C01-4FA8-8E87-E9EAD993B125 Q41925648-40A0ED84-E00D-4DA4-9F16-5592720435BC

P2860

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.

http://www.wikidata.org/entity/Q34527469

description

2016 nî lūn-bûn

@nan

2016 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

HIV-1 therapy with monoclonal ...... mmune responses against HIV-1.

@ast

HIV-1 therapy with monoclonal ...... mmune responses against HIV-1.

@en

HIV-1 therapy with monoclonal ...... mmune responses against HIV-1.

@nl

type

label

HIV-1 therapy with monoclonal ...... mmune responses against HIV-1.

@ast

HIV-1 therapy with monoclonal ...... mmune responses against HIV-1.

@en

HIV-1 therapy with monoclonal ...... mmune responses against HIV-1.

@nl

prefLabel

HIV-1 therapy with monoclonal ...... mmune responses against HIV-1.

@ast

HIV-1 therapy with monoclonal ...... mmune responses against HIV-1.

@en

HIV-1 therapy with monoclonal ...... mmune responses against HIV-1.

@nl

P1433

Q34527469-FF1B501D-41D3-4CEC-B921-D08DA005E564

P1476

Q34527469-DC08D7C1-9A10-424F-B469-3340B158E54E

P2093

Q34527469-035484FB-8F9B-43A1-8958-85BB27CB2D83

Q34527469-08D77041-3441-4464-9B1E-B736C095581B

Q34527469-199F7319-2844-427D-84B5-914E77FFFA88

Q34527469-27462205-49F5-4D3C-BF29-E0F47A2940DF

Q34527469-38793D67-7872-46AF-9611-458CBDF1D261

Q34527469-51C35988-9480-4FB7-820E-139EB95444DC

Q34527469-5AD99FEA-8C8C-4168-9D21-C2B6B2A9444F

Q34527469-5EDF194E-82B0-4227-B50B-22D0F8C27AE8

Q34527469-5FADB928-53BC-4F0E-AE79-8CB9FE4020EF

Q34527469-6F003EBF-E2DA-441C-B663-BCCC7D129A8A

P2860

Q34527469-07BE1072-E7CC-4C2E-AAE1-BE1BBF1CCE36

Q34527469-0EE65F22-94C4-44C4-B737-2AAAFEC435B5

Q34527469-14132628-F56B-4547-A010-3552DAD5D5B2

Q34527469-18AAED01-37C7-4FC4-9B3F-DB0B34B9E1A6

Q34527469-1CC14C8B-24F4-4DB3-9BAE-3112DEB2D277

Q34527469-20A3A4C1-8CED-4D54-8F47-D41066AD56F0

Q34527469-2527C403-E48D-4E59-BC0E-2A1497E935E1

Q34527469-268D4566-5545-467A-92DB-DC9F9602C11D

Q34527469-27B0F92C-4EDB-40F5-93C9-6E816705BB18

Q34527469-2C024981-04CB-4C41-976A-6294E00CD42C

P304

Q34527469-B44C3170-A1F0-4672-85F6-CD55EB6A034C

P31

Q34527469-85D5CC8B-A7F5-4184-A179-D819D8472B43

P356

Q34527469-425A2099-1ED3-437C-9481-912EB7FDD4D6

P407

Q34527469-9FAB08DC-4633-4614-BB54-083512883160

P433

Q34527469-49CBE9CB-A352-47FE-9F30-68CEE90FC797

P478

Q34527469-C3380156-D892-462E-9E96-1BDD2F860E1A

P50

Q34527469-06DF83F9-53F6-4701-836D-D398D8DBF0B6

Q34527469-11E87E75-548C-43AE-B131-BEEDC7B5EA03

Q34527469-2E158115-600F-48F9-ABC8-A4E37044E487

Q34527469-35DB814F-5A63-40B4-ADDB-2528BE87AE4E

Q34527469-48469E13-842E-4618-A562-66ED2DE5B404

Q34527469-828491EF-89F5-4221-A20A-647444360995

Q34527469-B50C587B-99EC-4925-9E0A-E135C6BEBAE3

P577

Q34527469-46623FBF-3024-40D2-A776-6A06A5BD0555

P698

Q34527469-91447C68-48C9-4F42-93E0-B59C428B4269

P921

Q34527469-B39AE3C3-ED71-4E0D-BD85-D9661375E7C4

P932

Q34527469-066D5B02-FD3B-461E-A9F0-A614C9E14F28

P356

SCIENCE.AAF0972

P1433

P1476

HIV-1 therapy with monoclonal ...... mmune responses against HIV-1.

@en

P2093

Anna Feldmann

http://www.w3.org/2001/XMLSchema#string

Anthony P West

http://www.w3.org/2001/XMLSchema#string

Edward F Kreider

http://www.w3.org/2001/XMLSchema#string

Erica H Parrish

http://www.w3.org/2001/XMLSchema#string

Florian Klein

http://www.w3.org/2001/XMLSchema#string

Gerald H Learn

http://www.w3.org/2001/XMLSchema#string

Julie Czartoski

http://www.w3.org/2001/XMLSchema#string

Julio C C Lorenzi

http://www.w3.org/2001/XMLSchema#string

Lilian Nogueira

http://www.w3.org/2001/XMLSchema#string

Malte Braunschweig

http://www.w3.org/2001/XMLSchema#string

P2860

The role of Fc-FcγR interactions in IgG-mediated microbial neutralization

Structural insights on the role of antibodies in HIV-1 vaccine and therapy

Antibodies in HIV-1 vaccine development and therapy

Virological features associated with the development of broadly neutralizing antibodies to HIV-1

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization

New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0

P304

997-1001

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCIENCE.AAF0972

http://www.w3.org/2001/XMLSchema#string

P407

P433

6288

http://www.w3.org/2001/XMLSchema#string

P478

352

http://www.w3.org/2001/XMLSchema#string

P50

Pamela J. Bjorkman

Michel C. Nussenzweig

Beatrice H. Hahn

Thiago Y Oliveira

P577

2016-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27199429

http://www.w3.org/2001/XMLSchema#string

P921

P932

5151174

http://www.w3.org/2001/XMLSchema#string